These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16413615)

  • 21. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases.
    Rissmann A; Pieper S; Adams I; Brune T; Wiemann D; Reinhold D
    Pediatr Allergy Immunol; 2009 May; 20(3):261-5. PubMed ID: 18761651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of complement-mediated immune damage by intravenous immune globulin.
    Basta M
    Clin Exp Immunol; 1996 May; 104 Suppl 1():21-5. PubMed ID: 8625538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin: implications for use in the neurological patient.
    Chipps E; Skinner C
    J Neurosci Nurs; 1994 Feb; 26(1):8-17. PubMed ID: 8195653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.
    Bayry J; Thirion M; Misra N; Thorenoor N; Delignat S; Lacroix-Desmazes S; Bellon B; Kaveri S; Kazatchkine MD
    Neurol Sci; 2003 Oct; 24 Suppl 4():S217-21. PubMed ID: 14598046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulin treatment of neurological autoimmune diseases.
    Stangel M; Hartung HP; Marx P; Gold R
    J Neurol Sci; 1998 Jan; 153(2):203-14. PubMed ID: 9511879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intravenous immunoglobulin treatment in autoimmune diseases].
    Danieli MG; Calcabrini L; Marchetti A; Calabrese V; Pettinari L; Massaccesi C; Gabrielli A; Danieli G
    Recenti Prog Med; 2007 Jun; 98(6):322-6. PubMed ID: 17580523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic mechanisms of interferon-beta and intravenous immunoglobulin for experimental peripheral neuropathy].
    Gao YX; Li SL; Han XZ; Sun Y; Yao CM
    Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):574-8. PubMed ID: 18021528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of antitoxin and antibacterial activity of human preparations of normal immunoglobulin. I. Level of tetanus antitoxin in preparations of IMIG and IVIG].
    Zakrzewska A; Rymkiewicz D
    Przegl Epidemiol; 1995; 49(4):381-4. PubMed ID: 8868196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin.
    Damianovich M; Solomon AS; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2007 Sep; 1110():567-77. PubMed ID: 17911473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors.
    Tha-In T; Metselaar HJ; Tilanus HW; Boor PP; Mancham S; Kuipers EJ; de Man RA; Kwekkeboom J
    Transplantation; 2006 Jun; 81(12):1725-34. PubMed ID: 16794540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity.
    Jacobi C; Claus M; Wildemann B; Wingert S; Korporal M; Römisch J; Meuer S; Watzl C; Giese T
    Clin Immunol; 2009 Dec; 133(3):393-401. PubMed ID: 19828380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
    Crow AR; Song S; Siragam V; Lazarus AH
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.
    Zhu KY; Feferman T; Maiti PK; Souroujon MC; Fuchs S
    J Neuroimmunol; 2006 Jul; 176(1-2):187-97. PubMed ID: 16730380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immunoglobulin therapy in dermatologic disorders.
    Cakmak SK; Gül U; Gönül M; Kiliç A; Soylu S
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):75-84. PubMed ID: 18691136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IVIG therapy: interfering with interferon-gamma.
    Clynes R
    Immunity; 2007 Jan; 26(1):4-6. PubMed ID: 17241954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.